Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers
Status:
Completed
Trial end date:
2021-09-08
Target enrollment:
Participant gender:
Summary
This study aimed to evaluate the pharmacokinetic characteristics and bioequivalence of two
olaparib tablets in patients with epithelial ovarian, fallopian tube, or primary peritoneal
cancer.